Literature DB >> 17196262

Immune control by endocannabinoids - new mechanisms of neuroprotection?

Oliver Ullrich1, Katrin Merker, Johanna Timm, Svantje Tauber.   

Abstract

The endocannabinoid system consists of cannabinoid receptors, their endogenous ligands and enzymes for synthesis and degradation of endocannabinoids and represents a local messenger system within and between the nervous and immune system. Apparently, the endocannabinoid system is involved in immune control and neuoprotection. In this review, we discuss possible mechanisms of immune control by endocannabinoids, which include the modulation of innate immunity, effects on cytokin networks, downregulation of adaptive immune response and apoptosis in immune cells.

Mesh:

Substances:

Year:  2006        PMID: 17196262     DOI: 10.1016/j.jneuroim.2006.11.018

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  16 in total

Review 1.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

Review 2.  Translational research in neurology and neuroscience 2010: multiple sclerosis.

Authors:  Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; Omar Khan; Todd N Eagar
Journal:  Arch Neurol       Date:  2010-07-12

Review 3.  Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.

Authors:  Esmée Vendel; Elizabeth C M de Lange
Journal:  Neuromolecular Med       Date:  2014-06-15       Impact factor: 3.843

Review 4.  Pharmacology of traumatic brain injury: where is the "golden bullet"?

Authors:  Kathryn Beauchamp; Haitham Mutlak; Wade R Smith; Esther Shohami; Philip F Stahel
Journal:  Mol Med       Date:  2008-08-18       Impact factor: 6.354

5.  The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action.

Authors:  D M Kerr; B Harhen; B N Okine; L J Egan; D P Finn; M Roche
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

6.  Disruption of IFN-gamma- mediated antiviral activity in neurons: the role of cannabinoids.

Authors:  R Antonio Herrera; Joseph H Oved; Carol Shoshkes Reiss
Journal:  Viral Immunol       Date:  2008-06       Impact factor: 2.257

Review 7.  Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Authors:  Til Menge; Martin S Weber; Bernhard Hemmer; Bernd C Kieseier; Hans-Christian von Büdingen; Clemens Warnke; Scott S Zamvil; Aaron Boster; Omar Khan; Hans-Peter Hartung; Olaf Stüve
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Temporal changes in mouse brain fatty acid amide hydrolase activity.

Authors:  S T Glaser; M Kaczocha
Journal:  Neuroscience       Date:  2009-06-23       Impact factor: 3.590

9.  Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors.

Authors:  Leyre Mestre; Paula M Iñigo; Miriam Mecha; Fernando G Correa; Miriam Hernangómez-Herrero; Frida Loría; Fabian Docagne; José Borrell; Carmen Guaza
Journal:  J Neuroinflammation       Date:  2011-08-18       Impact factor: 8.322

10.  Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors.

Authors:  Svantje Tauber; Katrin Paulsen; Susanne Wolf; Peggy Synwoldt; Andreas Pahl; Regine Schneider-Stock; Oliver Ullrich
Journal:  PLoS One       Date:  2012-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.